HomeCompareEVONX vs ABBV

EVONX vs ABBV: Dividend Comparison 2026

EVONX yields 28.19% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EVONX wins by $864182522.58M in total portfolio value
10 years
EVONX
EVONX
● Live price
28.19%
Share price
$7.09
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$864182522.69M
Annual income
$858,334,287,102,790.40
Full EVONX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — EVONX vs ABBV

📍 EVONX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVONXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVONX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVONX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVONX
Annual income on $10K today (after 15% tax)
$2,396.56/yr
After 10yr DRIP, annual income (after tax)
$729,584,144,037,371.80/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, EVONX beats the other by $729,584,144,016,315.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVONX + ABBV for your $10,000?

EVONX: 50%ABBV: 50%
100% ABBV50/50100% EVONX
Portfolio after 10yr
$432091261.39M
Annual income
$429,167,143,563,781.06/yr
Blended yield
99.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EVONX
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVONX buys
0
ABBV buys
0
No recent congressional trades found for EVONX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVONXABBV
Forward yield28.19%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$864182522.69M$102.3K
Annual income after 10y$858,334,287,102,790.40$24,771.77
Total dividends collected$863795329.41M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EVONX vs ABBV ($10,000, DRIP)

YearEVONX PortfolioEVONX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$16,339$5,638.97$11,550$430.00+$4.8KEVONX
2$34,704$17,221.47$13,472$627.96+$21.2KEVONX
3$105,505$68,371.23$15,906$926.08+$89.6KEVONX
4$501,407$388,516.81$19,071$1,382.55+$482.3KEVONX
5$3,987,740$3,451,235.01$23,302$2,095.81+$3.96MEVONX
6$55,571,609$51,304,726.56$29,150$3,237.93+$55.54MEVONX
7$1,395,840,783$1,336,379,162.13$37,536$5,121.41+$1395.80MEVONX
8$64,235,617,397$62,742,067,759.21$50,079$8,338.38+$64235.57MEVONX
9$5,465,640,731,550$5,396,908,620,934.50$69,753$14,065.80+$5465640.66MEVONX
10$864,182,522,685,549$858,334,287,102,790.40$102,337$24,771.77+$864182522.58MEVONX

EVONX vs ABBV: Complete Analysis 2026

EVONXStock

The fund seeks to achieve its investment objective by allocating its assets between a "Managed Futures" strategy and a "Fixed Income" strategy. The Adviser expects that less than 100%, typically 15-25%, of the fund's total net assets will be invested in and/or used as collateral for, gaining exposure to Managed Futures strategies. The adviser expects that less than 100%, typically 60-80%, of the fund's total net assets will be allocated to Fixed Income strategies.

Full EVONX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this EVONX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVONX vs SCHDEVONX vs JEPIEVONX vs OEVONX vs KOEVONX vs MAINEVONX vs JNJEVONX vs MRKEVONX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.